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We report darunavir, ritonavir, and etravirine pharmacokinetics in cervicovaginal fluid and blood plasma
for women from the Gender, Race and Clinical Experience (GRACE) study. Eight women received darunavir-
ritonavir (600/100 mg) twice daily (b.i.d.); two also received etravirine (200 mg) b.i.d. Week 4 paired blood
plasma and cervicovaginal fluid samples were collected over 12 h. Darunavir and etravirine cervicovaginal fluid
exposures were higher than blood plasma exposures; ritonavir cervicovaginal fluid exposure was lower than
blood plasma exposure. The high exposures of darunavir and etravirine in cervicovaginal fluid warrant further
evaluation of these drugs for use in HIV-1 prevention.
Primary HIV-1 prevention involves the use of antiretroviral
(ARV) therapy in an uninfected individual as pre- and postex-
posure prophylaxis to prevent initial viral replication. Second-
ary HIV-1 prevention strategies utilize ARVs in chronically
infected individuals to decrease HIV-1 replication in genital
secretions and reduce the risk of sexual transmission. Selection
of ARV agents for either primary or secondary HIV preven-
tion requires drugs to demonstrate both high genital tract
concentrations and antiretroviral efficacy (5, 9). The protease
inhibitors (PIs) and nonnucleoside reverse transcriptase inhib-
itors (NNRTIs) investigated to date have decreased penetra-
tion into cervicovaginal fluid (CVF) compared with that into
blood plasma (BP) (5, 6). However, there is substantial intra-
class and interclass variability in the degree of genital tract
penetration. Therefore, the pharmacokinetics (PK) of each
ARV in the genital tract compartment need to be evaluated
before each drug is considered for prevention of sexual trans-
mission of HIV-1.
The Gender, Race and Clinical Experience (GRACE) study
is the largest ARV trial in North America to focus on treat-
ment-experienced women with HIV and was designed to assess
sex-based differences in efficacy, safety, and tolerability of da-
runavir-ritonavir (DRV/r)-based therapy (3). The PK param-
eters of DRV, ritonavir (RTV), and etravirine (ETR) in CVF
and BP of HIV-1-infected women who participated in the
genital tract substudy of the GRACE trial are reported.
MATERIALS AND METHODS
Study design. The GRACE study (ClinicalTrials.gov identifier NCT00381303;
protocol TMC114-HIV3004) was a multicenter, open-label, phase 3b study that
enrolled treatment-experienced adults with HIV-1 RNA loads of at least 1,000
copies/ml (3). Subjects were excluded if, in the opinion of the investigator, they
required enfuvirtide to construct a viable ARV regimen or were receiving any
medication with known interactions with DRV, RTV, or ETR (3). Full inclusion
and exclusion criteria have been described previously (3). Patients received
DRV/r (600/100 mg) twice daily (b.i.d.), plus an investigator-selected optimized
background regimen (OBR) that could include ETR. The OBR was selected
based on resistance testing and included, on average, two fully active agents. This
genital tract analysis was a preplanned PK substudy and was designed to enroll
up to 15 premenopausal and 15 postmenopausal women. Human experimenta-
tion guidelines of the U.S. Department of Health and Human Services were
followed in the conduct of this clinical research.
Patients. Women from the GRACE study with an intact uterus who screened
negative for active sexually transmitted infections and were able to abstain from
sexual activity or douching for 48 h prior to genital tract sampling were eligible
to participate in the substudy. All patients provided written informed consent.
Study evaluations. Cervicovaginal fluid PK sampling was conducted in con-
junction with week 4 BP sampling. Participants who were adherent, as measured
by subject recall of timing of previous doses of study medication, were included.
Paired BP and self-collected, directly aspirated CVF samples were obtained
immediately predose and at 1, 2, 3, 4, 6, 9, and 12 h postdose. For premenopausal
women, CVF PK sampling was performed 5 to 10 days after completion of
menses; for postmenopausal women, genital tract sampling was not coordinated
with menses. A minimum of 50 l was required for analysis. Antiretroviral
concentrations were measured by validated liquid chromatography-mass spec-
trometry assays (2, 10) with an intra- and interday variability below 10% and a
dynamic range of 2 to 2,000 ng/ml. Data were analyzed by noncompartmental
methods, using WinNonlin (version 5.2.1). HIV-1 RNA in genital secretions was
measured using the Abbott Realtime HIV-1 0.6-ml protocol (Abbott Laborato-
ries, Abbott Park, IL). Plasma viral load was measured by quantitative PCR
(Amplicor HIV-1 Monitor v1.5; Roche Diagnostics, Branchburg, NJ). Since the
substudy was not powered for statistical comparisons, descriptive statistics are
reported. Unless otherwise noted, data are presented as medians (interquartile
ranges [IQR]).
RESULTS
Patient population and baseline characteristics. A total of
eight ARV-experienced women enrolled in the GRACE genital
tract substudy. Although the substudy was designed to enroll 30
women (15 premenopausal and 15 postmenopausal), the enroll-
ment target was not met due to a delay in site activation. There-
fore, the planned comparison between premenopausal and post-
menopausal women could not be performed. Results presented
henceforth are the combined results for the 6 premenopausal and
2 postmenopausal subjects. All subjects received DRV/r (600/100
mg) b.i.d., and two patients received ETR (200 mg) b.i.d. in their
OBR. The median (IQR) age was 44 (43 to 49) years, and the
median (IQR) body mass index was 25 (22 to 34) kg/m2. Seven
women were black, and one was Hispanic.
Pharmacokinetics of darunavir, ritonavir, and etravirine in
blood plasma and cervicovaginal fluid. DRV, ETR, and RTV
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were detected in 90%, 95%, and 86% of CVF samples,
respectively. Pharmacokinetic profiles can be found in Fig.
1, and PK parameters are described in Table 1. DRV and
ETR exposures in CVF were higher than those in BP, and
RTV exposure in CVF was slightly lower than that in BP.
Drug exposures in CVF were compared to those in BP by
using the median and IQR for the areas under the concen-
tration-time curves (AUC). The median AUCCVF:BP ratios
(IQR) were 1.5 (1.0 to 1.6) for DRV, 1.3 for ETR, and 0.8
(0.6 to 1.6) for RTV.
HIV-1 RNA in blood plasma and cervicovaginal fluid. For
the eight study participants, the median HIV-1 RNA load in
FIG. 1. Median (interquartile range) concentrations of darunavir (n  8) (top), ritonavir (n  8) (middle), and etravirine (n  2) (bottom) in
blood plasma and cervicovaginal fluid. The points and whiskers on the graphs represent the median values and interquartile ranges, respectively.
a, protein-adjusted half-maximal effective concentration.
TABLE 1. Darunavir, ritonavir, and etravirine exposures in blood plasma and cervicovaginal fluid
PK parametera
Median value (IQR)
Darunavir (n  8) Ritonavir (n  8) Etravirineb (n  2)
BP CVF BP CVF BP CVF
Cmax (ng/ml) 7,045 (4,954–8,015) 12,020 (7,951–14,032) 696 (547–1,134) 735 (612–1,603) 873 4,558
Tmax (h) 2.5 (2–3) 5 (3–7) 4 (4–6) 7 (3–10) 4 5
AUC12h (ng  h/ml) 63,371 (40,604–67,641) 73,037 (52,414–101,752) 4,572 (3,505–7,385) 5,601 (3,306–6,959) 8,870 11,963
CVF/BP AUC12h ratio
c 1.5 (1.0–1.6) 0.8 (0.6–1.6) 1.3
a Cmax, maximum plasma concentration; Tmax, time to reach Cmax; AUC12h, area under the concentration-time curve at 12 h.
b Data are medians only.
c Data represent the medians (IQR) of the individual ratios rather than the median concentrations.
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BP was 5.1 (range, 3.2 to 5.6) log10 copies/ml at baseline and
2.7 (range, 1.7 to 3.3) log10 copies/ml at week 4. All subjects
had a decrease in HIV RNA (range, 0.5 to 3.2 log10 copies/ml).
Among the eight participants, baseline HIV-1 RNA loads in
CVF were available for five women (range, 2.5 to 6.1 log10
copies/ml, or 320 to 1,184,080 copies/ml). Only two subjects
had evaluable CVF at week 4, and both of their HIV-1 RNA
loads were 2.8 log10 copies/ml (or 640 copies/ml). For the
remaining six participants, either the participants had less than
the required 800 l of CVF needed for the HIV-1 RNA assay or
the reverse transcription-PCR (RT-PCR) was inhibited for their
samples. Due to the small numbers of CVF samples that were
available for HIV-1 RNA analyses, no correlation analysis be-
tween drug exposure and HIV RNA response was performed.
DISCUSSION
This study investigated DRV, RTV, and ETR exposures in
BP and CVF. Our data show that DRV and ETR achieved
more penetration into CVF than other PIs and NNRTIs eval-
uated to date (4, 5; A. J. Jones et al., presented at the 10th
International Workshop on Clinical Pharmacology of HIV
Therapy, 15 to 17 April 2009, Amsterdam, Netherlands). DRV
exposure in the female genital tract was 1.5-fold higher than
that in BP. All concentrations of DRV in CVF were above the
protein-adjusted 50% effective concentration (EC50) for wild-
type virus (55 ng/ml) or resistant virus (550 ng/ml) (1, 11).
This relative CVF exposure was 3- to 20-fold higher than
what has been reported for other PIs. For example, the CVF
exposures of atazanavir and lopinavir are 20% and 10%,
respectively, of those in BP (6). Indinavir is the only PI that
shows higher CVF and BP exposures than darunavir (200%
versus 150%, respectively). Etravirine exposure in CVF was
30% higher than that in BP, in contrast to the case for
efavirenz, which shows minimal penetration into CVF
(1% of BP penetration) (5). However, the ETR data from
this study were based on a small sample size (n  2), which
limits any forecasting of its use in the prevention arena until
more data are available. Ritonavir exposure in the female
genital tract was higher in this study than in previous eval-
uations, in which RTV exposure in CVF was 25% that in BP
(5), although RTV concentrations in the CVF in this study
were still lower than those in the BP (80% of BP exposure).
This substudy of the GRACE study did not reach the
target enrollment of 15 premenopausal and 15 postmeno-
pausal women, predominantly due to a delay in substudy
initiation. There were, however, sufficient numbers of pre-
menopausal women who received DRV to evaluate steady-
state genital tract exposure in this population. In general,
the high penetration level of DRV into the female genital
tract suggests that DRV may be beneficial in preventing the
sexual transmission of HIV-1 and in preventing the devel-
opment of compartmental viral resistance. A direct associ-
ation between increased ARV penetration into the female
genital tract and eradication of infectiousness has not been
demonstrated. However, the low level of penetration into
the female genital tract of the first-generation NNRTIs has
been linked with increased HIV-1 shedding at the cervix
compared with that with PIs (with and without low-dose
RTV), which have better penetration (7).
Large volumes of CVF are required for HIV-1 RNA quantifi-
cation (800 l is required to detect a level of 200 copies/ml).
Despite pooling of all remaining CVF after PK analyses for each
individual, this study was not able to adequately evaluate cervical
shedding of HIV-1 RNA in all subjects. Therefore, no correlation
between drug exposure and infectiousness can be made. Under-
standing this correlation in the female genital tract is important as
treatment guidelines evolve. Further evaluation of the pharma-
cokinetic-pharmacodynamic relationship and the development of
viral resistance among individual ARVs is necessary. While this
substudy evaluated ARV penetration under steady-state condi-
tions, further investigation will also be needed to assess single-
dose PK of DRV and ETR in order to understand their role in
primary prevention. Nonetheless, the CVF penetration of DRV
was similar to those of other ARVs (including tenofovir, which
has a CVF/BP penetration ratio of 110%) that are being investi-
gated for primary prophylaxis (5, 8).
The high exposures of DRV and ETR in the female genital
tract suggest that both ARVs may be effective in primary and
secondary HIV-1 prevention strategies beyond reduction of
plasma HIV-1 RNA. Further research is warranted to define
the effects of DRV and ETR on HIV-1 RNA, and thus infec-
tiousness, in the female genital tract.
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